Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Abstract

Omalizumab has the potential to be an additional and solitary treatment option in patients with CF and ABPA. Early onset treatment may be beneficial and patients with early stage of lung disease seem to benefit more.